Shares jumped as CEO Eric Lefkofsky took the stage at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, painting an aggressive long-term growth picture that sent TEM up 10.4% to $68.65. The rally marks a 17% climb from last week's $58.74 low but pushes the stock above the consensus analyst price target, raising a pointed question: is management's optimism already priced in?
• Pharma Data Deals Are Getting Bigger — and Stickier
Insights sub-segment revenue — where Tempus licenses its massive trove of patient genomic and clinical data to drugmakers — increased 36% in Q2, reflecting strong demand for data licensing and modeling. Management told the Morgan Stanley audience this business has now produced three consecutive quarters exceeding $100 million in total contract value. Strategic collaborations with major pharma companies include recent multi-year, $100M+ deals. That recurring pharma demand is what gives the ~25% long-term growth target its credibility — and its highest-margin fuel.
• Diagnostics Keep the Engine Running While Data Scales
Diagnostics revenue reached $289.3 million in Q2, representing 20% year-over-year growth, supported by 31% oncology volume growth.
An FDA-cleared tumor-only companion diagnostic test could enable unified pricing and an estimated $85 million annual revenue uplift starting in 2027. Diagnostics isn't the glamour business, but it feeds the data library that pharma clients pay to access — a self-reinforcing loop that competitors struggle to replicate.
• Profitability Is Close, but GAAP Losses Still Linger
Management described Q2 as exceptional, and the company recorded net income of $5.6 million — compared with a net loss of $42.8 million a year earlier. Yet first-half 2026 net loss was still $120.3 million, and the company used $80.8 million of cash in operations. Management expects positive free cash flow by year-end, but that still depends on sustained booking velocity.
• The Stock Now Trades Above Most Analyst Targets
The average 12-month price target among 15 analysts is $65.57, with a high of $80 and a low of $45. At $68.65, the stock has already overshot the consensus by roughly 5%. BTIG recently raised its target to $80, and H.C. Wainwright lifted to $66. Investors are betting management delivers on the 25% growth floor and closes the $1.5–$1.7 billion Personalis acquisition without stumbling. Any execution miss could snap the stock back hard.